[go: up one dir, main page]

AR057746A1 - Peg-ifn alfa y ribavirina para el tratamiento del virus de hepatitis b - Google Patents

Peg-ifn alfa y ribavirina para el tratamiento del virus de hepatitis b

Info

Publication number
AR057746A1
AR057746A1 ARP060103536A ARP060103536A AR057746A1 AR 057746 A1 AR057746 A1 AR 057746A1 AR P060103536 A ARP060103536 A AR P060103536A AR P060103536 A ARP060103536 A AR P060103536A AR 057746 A1 AR057746 A1 AR 057746A1
Authority
AR
Argentina
Prior art keywords
peg
treatment
hepatitis
ribavirine
virus
Prior art date
Application number
ARP060103536A
Other languages
English (en)
Inventor
Henricus Leonardus Ant Janssen
Nigel Pluck
Matei Popescu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37654895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057746(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR057746A1 publication Critical patent/AR057746A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Uso de conjugados de PEG-IFN-alfa en asociacion con ribavirina para el tratamiento de infecciones de hepatitis B cronica. Método para tratar infecciones de hepatitis B cronica en pacientes que necesitan dicho tratamiento que comprende la administracion de una cantidad de conjugado de PEG-IFN-alfa en asociacion con una cantidad de ribavirina efectiva para tratar la hepatitis B cronica.
ARP060103536A 2005-08-15 2006-08-14 Peg-ifn alfa y ribavirina para el tratamiento del virus de hepatitis b AR057746A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05107473 2005-08-15

Publications (1)

Publication Number Publication Date
AR057746A1 true AR057746A1 (es) 2007-12-12

Family

ID=37654895

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103536A AR057746A1 (es) 2005-08-15 2006-08-14 Peg-ifn alfa y ribavirina para el tratamiento del virus de hepatitis b

Country Status (16)

Country Link
US (2) US20070071720A1 (es)
EP (1) EP1917037A2 (es)
JP (1) JP2009504706A (es)
KR (1) KR20080027944A (es)
CN (1) CN101242857A (es)
AR (1) AR057746A1 (es)
AU (1) AU2006281498A1 (es)
BR (1) BRPI0614863A2 (es)
CA (1) CA2617958A1 (es)
IL (1) IL188962A0 (es)
MX (1) MX2008002015A (es)
NO (1) NO20080495L (es)
RU (1) RU2008109649A (es)
TW (1) TW200740455A (es)
WO (1) WO2007020195A2 (es)
ZA (1) ZA200801248B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8623348B2 (en) * 2009-03-27 2014-01-07 Jw Pharmaceutical Corporation Interferon-α (IFN-α) fused proteins comprising IFN-α and a cytoplasmic transduction peptide (CTP)
IN2015DN01371A (es) * 2012-08-13 2015-07-03 Jw Creagene Inc
AR112166A1 (es) * 2017-06-16 2019-09-25 Arbutus Biopharma Corp Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
US20230207064A1 (en) * 2021-12-29 2023-06-29 Illumina, Inc. Inter-model prediction score recalibration during training

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
RS50144B (sr) * 1998-06-08 2009-03-25 F. Hoffmann-La Roche Ag., Primena peg-inf-alfa 2a i ribavirina za proizvodnju leka za lečenje hroničnog hepatitisa c
BR0314259A (pt) * 2002-09-13 2005-07-26 Idenix Cayman Ltd ß-l-2'-desoxinucleosìdeos para o tratamento de cepas de hbv resistentes e terapias combinadas
AU2003282883B2 (en) * 2002-11-18 2008-12-04 Polaris Group Methods for inhibiting viral replication in vivo
WO2005067963A1 (en) * 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
WO2006010256A1 (en) * 2004-07-26 2006-02-02 Transition Therapeutics Inc. Compositions and methods comprising vitamin b12 and an impdh inhibitor for treating viral, inflammatory and proliferative diseases
EP1789043A2 (en) * 2004-08-13 2007-05-30 Migenix Inc. Compositions and methods for treating or preventing hepadnaviridae infection
CN101166750A (zh) * 2004-10-29 2008-04-23 拜奥克里斯特制药公司 治疗用呋喃并嘧啶类化合物和噻吩并嘧啶类化合物
BRPI0516922A (pt) * 2004-11-02 2008-09-23 New River Pharmaceuticals Inc composto de ribavirina, método para fazer um composto de ribavirina, método para usar um composto de ribavirina e composição farmacêutica
MX2007015085A (es) * 2005-05-31 2008-01-17 Novartis Ag Tratamiento de enfermedades del higado en donde el hierro juega un papel importante en patogenesis.

Also Published As

Publication number Publication date
WO2007020195A3 (en) 2007-05-24
CA2617958A1 (en) 2007-02-22
BRPI0614863A2 (pt) 2011-04-19
KR20080027944A (ko) 2008-03-28
NO20080495L (no) 2008-03-10
JP2009504706A (ja) 2009-02-05
US20080317714A1 (en) 2008-12-25
US20070071720A1 (en) 2007-03-29
ZA200801248B (en) 2008-11-26
EP1917037A2 (en) 2008-05-07
CN101242857A (zh) 2008-08-13
WO2007020195A2 (en) 2007-02-22
IL188962A0 (en) 2008-08-07
TW200740455A (en) 2007-11-01
AU2006281498A1 (en) 2007-02-22
RU2008109649A (ru) 2009-09-27
MX2008002015A (es) 2008-03-25

Similar Documents

Publication Publication Date Title
CL2008001855A1 (es) Compuestos ciclicos condensados derivados del boro; composicion farmaceutica; y uso en el tratamiento y/o prevencion de una enfermedad infecciosa.
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
BRPI0513370A (pt) uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
DK2219642T3 (da) Silibininbestandel til behandling af hepatitis
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
CL2007002490A1 (es) Metodos para el tratamiento de un huesped vivo que tiene una infeccion por el virus de hepatitis c; composicion para el tratamiento de la infeccion por hepatitis c; y un producto de elaboracion para la administracion de terapia combinada para el trat
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
MX2022007908A (es) Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
CY1110182T1 (el) Ιδεβενονη για τη θεραπεια των μυϊκων δυστροφιων
BRPI0509927A (pt) composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina
ECSP077423A (es) Coadministración de tigeciclina y digoxin
AR057746A1 (es) Peg-ifn alfa y ribavirina para el tratamiento del virus de hepatitis b
ES2325291A1 (es) "uso de un extracto de silybum marianum"
FR2886850B1 (fr) Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee
ATE536368T1 (de) Konjugate von zytotoxischen verbindungen mit peptiden
EA200801890A1 (ru) Средство для лечения шума в ушах
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
AR067351A1 (es) Combinacion de picotamida con nafronil
ECSP993003A (es) Uso de peg - ifn -alpha y ribavirina para el tratamiento de hepatitis c cronica
AR077460A1 (es) Uso de la combinacion de teriflunomida e interferon beta para el tratamiento de la esclerosis multiple
EA200801023A1 (ru) Применение фенофибрата или его производного для предотвращения диабетической ретинопатии
TH87484A (th) Peg-ifn อัลฟา และริบาวิรินสำหรับรักษา hbv

Legal Events

Date Code Title Description
FB Suspension of granting procedure